A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström’s macroglobulinemia

Naohiro Sekiguchi1 | Shinya Rai2 | Wataru Munakata3 | Kenshi Suzuki4
Hiroshi Handa5 | Hirohiko Shibayama6 | Tomoyuki Endo7 | Yasuhiro Terui8
Noriko Iwaki9 | Noriko Fukuhara10 | Hiro Tatetsu11 | Shinsuke Iida12
Takayuki Ishikawa13 | Ryota Shiibashi14 | Koji Izutsu3

1Department of Hematology, National Hospital Organization Disaster Medical Center, Tachikawa, Japan
2Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka, Japan
3Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
4Department of Hematology, Juntendo University, Tokyo, Japan
5Department of Hematology, Gunma University School of Medicine, Maebashi, Japan
6Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan
7Department of Hematology, Hokkaido University Hospital, Sapporo, Japan
8Department of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
9Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan
10Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan
11Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan
12Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

Abstract

Tirabrutinib is a second-generation Bruton’s tyrosine kinase inhibitor with greater selectivity than ibrutinib. Here, we conducted a multicenter, phase II study of tirabrutinib in patients with treatment-naive (Cohort A) or with relapsed/refractory (Cohort B) Waldenström’s macroglobulinemia (WM). Patients were treated with tirabrutinib 480 mg once daily. The primary endpoint was major response rate (MRR; ≥ partial response). Secondary endpoints included overall response rate (ORR; ≥ minor response), time to major response (TTMR), progression-free survival (PFS), overall survival (OS), and safety. In total, 27 patients (18 in Cohort A; 9 in Cohort B) were enrolled. The median age was 71 y, and the median serum immunoglobulin M level was 3600 mg/dL. Among the patients, 96.2% had the MYD88L265P mutation. MRR and ORR were 88.9% and 96.3%, respectively (Cohort A: MRR, 88.9%; ORR, 94.4%; Cohort B: MRR, 88.9%; ORR, 100%). Median TTMR was 1.87 mo. PFS and OS were not reached with a median follow-up of 6.5 and 8.3 mo for Cohorts A and B, respectively. The most common adverse events (AEs) were rash (44.4%), neutropenia (25.9%), and leukopenia (22.2%), with most AEs classified as grade 1 or 2. Grade ≥ 3 AEs included neutropenia (11.1%), lymphopenia (11.1%), and leukopenia (7.4%). No grade 5 AEs were noted. All bleeding events were grade 1; none were associated with drug-related atrial fibrillation or hypertension. Although the follow-up duration was relatively short, the study met the primary endpoint. Therefore, tirabrutinib monotherapy is considered to be highly effective for both untreated and relapsed/refractory WM with a manageable safety profile. (JapicCTI-173646).

Abbreviations: AE, adverse event; AS-PCR, allele-specific polymerase chain reaction; BTK, Bruton’s tyrosine kinase; CI, confidential interval; CLL, chronic lymphocytic leukemia; CR, complete response; CT, computed tomography; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; IPSSWM, International Prognostic Scoring System for Waldenström's macroglobulinemia; IRC, independent review committee; MR, minor response; MRR, major response rate; NGS, next-generation sequencing; ORR, overall response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SPD, sum of the products of the greatest diameters; TTMR, time to major response; TTOR, time to overall response; VGPR, very good partial response; WHIM, warts, hypogammaglobulinemia infection, and myelokathexis syndrome; WM, Waldenström’s macroglobulinemia.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association
1 INTRODUCTION

Waldenström’s macroglobulinemia (WM) is a major type of lymphoplasmacytic lymphoma that is characterized by the infiltration of neoplastic B cells with plasmacytic differentiation into bone marrow and IgM monoclonal gammopathy. Several treatment options for WM have been developed, including rituximab monotherapy, chemoinmunotherapy, and bortezomib-based treatments. However, WM typically progresses despite treatment in most patients. In addition, hematologic and non-hematologic toxicities, including peripheral neuropathy, infections, and secondary malignancies, remain major concerns for these treatments. Therefore, the development of new treatment strategies is necessary.

BTK is predominantly expressed in B cells, where it plays a critical role in B-cell development and function. However, in B-cell lymphoma, the BTK-mediated signal cascade is constitutively activated, and knockdown of BTK is shown to reduce the survival of malignant B cells. In WM, a mutation in MYD88 serves to support the survival of lymphoplasmacytic cells via BTK activation. This mutation (MYD88<sup>L265</sup>) has been found to be present in the majority of patients with WM and triggers nuclear factor kappa B activation via phosphorylated BTK. Therefore, BTK inhibition is considered a promising therapeutic option for WM.

Ibrutinib is an irreversible selective inhibitor for BTK and has been shown to be highly effective for WM. A randomized phase III trial demonstrated a higher response rate in patients treated with ibrutinib and rituximab compared with those treated with rituximab alone (iNNOVATE Study). However, safety remains a major concern regarding ibrutinib treatment, with several adverse effects noted, including atrial fibrillation, bleeding events, and hypertension. This is likely because ibrutinib has some off-target effects, including inhibition of other tyrosine kinases such as EGFR, tyrosine kinase expressed in hepatocellular carcinoma, the phosphoinositide 3-kinase/AKT cardio protective pathway, and interleukin-2-inducible T-cell kinase. A systematic review and meta-analysis of ibrutinib treatment for patients with CLL demonstrated an increased risk of these toxicities, which led to the discontinuation of ibrutinib. Thus, the development of an effective treatment for WM with a reduced incidence of these toxicities would contribute to a longer response duration.

Tirabrutinib (ONO/GS-4059) is a highly potent and selective second-generation BTK inhibitor. Tirabrutinib forms a covalent bond with BTK and has demonstrated effective in vitro cytotoxicity in B-cell lymphoma and in vivo antitumor activity in mouse models. Multicenter, dose-escalation phase I trials of tirabrutinib for relapsed or refractory CLL and B-cell lymphoma, including WM, have demonstrated the efficacy and tolerability of tirabrutinib.

Therefore, we conducted a multicenter, open-label, phase II study of tirabrutinib to evaluate its efficacy and safety in patients with WM.

2 MATERIALS AND METHODS

2.1 Trial design and treatment

This phase II trial (Japan Pharmaceutical Information Center clinical trial ID: JapicCTI-173646) was conducted with an open-label and single-arm design at 19 sites in Japan. The enrollment of patients began on November 8, 2018 and closed on February 22, 2019. All authors had full access to the primary data.

Tirabrutinib was administered orally under fasting conditions at a daily dose of 480 mg for 28 d as 1 cycle. Tirabrutinib was continued until disease progression or clinically unacceptable toxicity. The dose was determined based on safety and efficacy data obtained in previous clinical trials. During the study, the administration of tirabrutinib would be interrupted due to AEs and, after recovery, a reduced dose of 320 or 160 mg/d would be administered at the physician’s discretion.

2.2 Patients

Patients histologically diagnosed with WM were enrolled into 2 cohorts. Patients in Cohort A were treatment-naïve patients, and those in Cohort B were relapsed or refractory patients who received 1 or more lines of systemic treatment for WM. The inclusion criteria in Cohort A were either presence of symptomatic WM or serum IgM levels of >4000 mg/dL. Other major eligibility criteria for both cohorts included age ≥ 20 y, monoclonal gammopathy with serum
IgM levels of >500 mg/dL, an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1, and acceptable laboratory test results. The International Prognostic Scoring System for WM (IPSSWM) score was also categorized. Major exclusion criteria were tumor lesions in the central nervous system and prior administration of BTK inhibitors.

### 2.3 MYD88 and CXCR4 genotyping

Genomic DNA was isolated from bone marrow and/or tumor tissues. The L265P mutation in MYD88 was specifically assessed by real-time polymerase chain reaction using an allele-specific oligonucleotide (AS-PCR). Mutations in CXCR4 were analyzed using the Ion Torrent PGM NGS system (Life Technologies Japan Ltd.). The occurrence of warts, hypogammaglobulinemia infection, and myelokathexis syndrome (WHIM)-like mutations in CXCR4, hereafter referred to as CXCR4\textsuperscript{WHIM}, were a particular focus of this study.

### 2.4 Efficacy and safety

The primary endpoint of this study was MRR, as assessed by an IRC according to the consensus criteria of the VIth International Workshop for Waldenström’s Macroglobulinemia. The consensus categories for the response comprised CR, VGPR, PR, MR, stable disease, and PD. Major response was defined to include CR, VGPR, and PR. The overall response was defined to include the major response and MR. The major secondary endpoints were the ORR, TTMR, TTOR, duration of major response, PFS, OS, decreases in serum IgM and in the sizes of measurable lesions in the lymph nodes and extramedullary diseases by CT, and changes in primary disease-associated clinical symptoms, including hemoglobin levels. The lesion size was defined as the sum of the products of the greatest diameters (SPD). Serum IgM and SPD were monitored before the first administration, at the end of the first cycle, and at the beginning of each odd-numbered cycle.

AEs that occurred during administration, within 28 d after completion of administration of the study drug, and before the start of a subsequent therapy were evaluated, as were death and the data cutoff point. AEs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

### 2.5 Statistics

The expected MRR of Cohorts A and B were 80.0% and 70.0%, respectively. The required number of patients in each cohort was 18 in Cohort A and 8 in Cohort B. This was calculated so that the study would show that the lower limit of the 95% CI for the MRR was higher than the threshold response rates of 45.0% (Cohort A) and 20.0% (Cohort B), with a probability of at least 80%. Baseline characteristics were analyzed for all enrolled patients, including the efficacy in patients having one or more response scores as evaluated by the IRC after the administration of tirabrutinib and the safety in patients administered with at least 1 dose of tirabrutinib. The data cutoff point was August 28, 2019, which was the first day of the seventh cycle for the latest-enrolled patient. The Clopper-Pearson method was used to estimate the 95% CIs for the MRR and ORR. No adjustments were made for covariates. The maximum reduction ratios of serum IgM levels and the measurable lesion sizes by CT were assessed using waterfall plots.

### 3 RESULTS

#### 3.1 Patient characteristics

Among the 30 patients who provided informed consent, 18 treatment-naïve patients with WM were enrolled in Cohort A and 9 relapsed or refractory patients were enrolled in Cohort B (Figure 1;
|                      | Cohort A Treatment-naïve N = 18 | Cohort B Relapsed/refractory N = 9 | Total N = 27 |
|----------------------|---------------------------------|-----------------------------------|--------------|
| **Sex**              |                                 |                                   |              |
| Female               | 3 (16.7)                        | 2 (22.2)                          | 5 (18.5)     |
| Male                 | 15 (83.3)                       | 7 (77.8)                          | 22 (81.5)    |
| **Age**              |                                 |                                   |              |
| Median (y)           | 70.5 (50-82)                    | 71 (60-83)                        | 71 (50-83)   |
| **IPSSWM**           |                                 |                                   |              |
| Low risk             | 3 (16.7)                        | 2 (22.2)                          | 5 (18.5)     |
| Intermediate risk    | 8 (44.4)                        | 5 (55.6)                          | 13 (48.1)    |
| High risk            | 7 (38.9)                        | 2 (22.2)                          | 9 (33.3)     |
| **Serum IgM**        |                                 |                                   |              |
| Median (mg/dL)       | 3787.5 (1392-6340)              | 2105.0 (730-6930)                 | 3600.0 (730-6930) |
| ≤4000 mg/dL          | 11 (61.1)                       | 7 (77.8)                          | 18 (66.7)    |
| >4000 mg/dL          | 7 (38.9)                        | 2 (22.2)                          | 9 (33.3)     |
| **Hemoglobin**       |                                 |                                   |              |
| Median (g/dL)        | 10.45 (8.0-15.3)                | 12.20 (9.1-13.9)                  | 10.60 (8.0-15.3) |
| **Platelet count**   |                                 |                                   |              |
| Median (10⁹/L)       | 257.5 (67-441)                  | 206.0 (79-311)                    | 257.0 (67-441) |
| **β₂-microglobulin** |                                 |                                   |              |
| Median (mg/L)        | 3.150 (1.60-9.70)               | 3.200 (1.70-5.50)                 | 3.200 (1.60-9.70) |
| **Lymphadenopathy**  |                                 |                                   |              |
| Yes                  | 8 (44.4)                        | 6 (66.7)                          | 14 (51.9)    |
| **Splenomegaly**     |                                 |                                   |              |
| Yes                  | 10 (55.6)                       | 4 (44.4)                          | 14 (51.9)    |
| **Hyperviscosity**   |                                 |                                   |              |
| Yes                  | 6 (33.3)                        | 1 (11.1)                          | 7 (25.9)     |
| **Gene mutations**   |                                 |                                   |              |
| MYD88<sup>L265P</sup> | 16 (94.1)                     | 9 (100.0)                         | 25 (96.2)    |
| CXCR4<sup>WHIM</sup> | 4 (23.5)                        | 0                                 | 4 (15.4)     |
| MYD88<sup>WT</sup> / | 1 (5.9)                         | 0                                 | 1 (3.8)      |
| CXCR4<sup>WHIM</sup> |                                 |                                   |              |
| MYD88<sup>L265P</sup> / | 13 (76.5)                    | 9 (100.0)                         | 22 (84.6)    |
| CXCR4<sup>WT</sup>   |                                 |                                   |              |
| MYD88<sup>L265P</sup> / | 3 (17.6)                     | 0                                 | 3 (11.5)     |
| CXCR4<sup>WHIM</sup> |                                 |                                   |              |
| **Number of prior therapies** |                     |                                   |              |
| Median (range)       | NA                              | 2.0 (1-7)                         | NA           |
| 1                    | NA                              | 3 (33.3)                          | NA           |
| 2                    | NA                              | 3 (33.3)                          | NA           |
| ≥3                   | NA                              | 3 (33.3)                          | NA           |
| **Prior therapies**  |                                 |                                   |              |
| Rituximab            | NA                              | 8 (88.9)                          | NA           |
| Bortezomib           | NA                              | 3 (33.3)                          | NA           |
| Bendamustine         | NA                              | 3 (33.3)                          | NA           |
| Other alkylating agents | NA                          | 6 (66.7)                          | NA           |

**Note:** Data are numbers of patients (%) or median (range).
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; IPSSWM, International Prognostic Staging System for Waldenström's Macroglobulinemia; NA, not applicable.

<sup>a</sup>Gene mutation data were missing in 1 patient in Cohort A.
Table 1). All 27 patients met the criteria for efficacy and safety analyses. At median follow-ups of 6.5 and 8.3 mo for Cohort A and Cohort B, respectively, 24 patients continued the administration (Figure 2). One patient in Cohort B discontinued the administration due to PD, 1 in Cohort A discontinued due to an AE, and another in Cohort A discontinued at the physician's discretion following the patient’s request of study drug discontinuation after PR.

The baseline demographics, clinical characteristics, baseline laboratory values, IPSSWM scores, and genotypes of the enrolled patients are listed in Table 1. The overall median age was 71 y (range, 50-83), with the median age of Cohort A 70.5 y (range, 50-82) and that of Cohort B 71 y (range, 60-83). The overall median baseline serum IgM level was 3600 mg/dL (range, 730-6930), with that of Cohort A 3788 mg/dL (range, 1392-6340) and that of Cohort B 2105 mg/dL (range, 730-6930). The number of patients in whom the baseline serum IgM level was >4000 mg/dL was 9 (33.3%), with 7 (38.9%) in Cohort A and 2 (22.2%) in Cohort B. Prior systemic therapies administered to Cohort B included rituximab in 8 patients (88.9%), bortezomib in 3 patients (33.3%), bendamustine in 3 patients (33.3%), and other alkylating agents in 6 patients (66.7%). No patients received purine analogs, such as fludarabine, or autologous transplantation. The majority (96.2%) of the patients (16 in Cohort A and 9 in Cohort B) were identified to have a mutation in MYD88.

### 3.2 Efficacy

The MRR and ORR in all patients were 88.9% and 96.3%, respectively. The MRR was 88.9% in both Cohort A (16 patients, including 3 patients exhibiting VGPR; 95% CI, 65.3-98.6) and Cohort B (8 patients; 95% CI, 51.8-99.7) (Table 2). The ORRs were 94.4% (17 patients; 95% CI, 72.7-99.9) and 100% (9 patients; 95% CI, 66.4-100.0) in Cohorts A and B, respectively. The median TTOR and TTMR in all patients were 0.95 (range, 0.9-3.9) and 2.00 (range, 1.0-5.7) mo; in Cohort A, 0.95 (range, 0.9-3.9) and 1.87 (range, 1.0-5.7) mo; and in Cohort B, 0.99 (range, 0.9-1.9) and 2.07 (range, 1.0-3.7) mo, respectively (Figure 2: Table 2). Because all the major responders, with 1 exception, achieved a major response by the data cutoff point, the median duration of the major response was not reached in either cohort.

The L265P mutation in MYD88, as assessed by AS-PCR, was found in 94.1% and 100% of patients in Cohorts A and B, respectively, whereas CXCR4WHIM, as assessed by NGS, was only found in 23.5% of patients in Cohort A (Table 1). The IRC-assessed responses in the patient subpopulations were classified according to the mutations in MYD88 and CXCR4 and are summarized in Table 2 and Supporting Information, Table S1. Briefly, the MRRs in patients with MYD88L265P/CXCR4WT (90.9%; 95% CI, 70.8-98.9) were relatively higher than those in patients with MYD88L265P/CXCR4WHIM (66.7%; 95% CI, 9.43-99.2). The median TTMRs were comparable between
```markdown
| Genotype                      | Cohort A N = 18 | Cohort B N = 9 | ALL N = 27 | ALL N = 26a |
|-------------------------------|-----------------|----------------|------------|-------------|
|                               | All N = 18      | All N = 9      | All N = 27 | MYD88<sup>WT</sup> CXCR4<sup>WHIM</sup> |
|                               |                 |                |            | N = 1       |
|                               |                 |                |            | MYD88<sup>L265P</sup> CXCR4<sup>WT</sup> |
|                               |                 |                |            | N = 22      |
|                               |                 |                |            | MYD88<sup>L265P</sup> CXCR4<sup>WHIM</sup> |
|                               |                 |                |            | N = 3       |

### Response rates – % (95% CI)

- **MRR (CR + VGPR + PR)**
  - Cohort A: 88.9 (65.3-98.6)
  - Cohort B: 88.9 (51.8-99.7)
  - ALL: 88.9 (70.8-97.6)
  - MYD88<sup>WT</sup> CXCR4<sup>WHIM</sup>: 100 (2.50-100)
  - MYD88<sup>L265P</sup> CXCR4<sup>WT</sup>: 90.9 (70.8-98.9)
  - MYD88<sup>L265P</sup> CXCR4<sup>WHIM</sup>: 66.7 (9.43-99.2)

- **ORR (CR + VGPR + PR + MR)**
  - Cohort A: 94.4 (72.7-99.9)
  - Cohort B: 100 (66.4-100)
  - ALL: 96.3 (81.0-99.9)
  - MYD88<sup>WT</sup> CXCR4<sup>WHIM</sup>: 100 (2.50-100)
  - MYD88<sup>L265P</sup> CXCR4<sup>WT</sup>: 95.5 (77.2-99.9)
  - MYD88<sup>L265P</sup> CXCR4<sup>WHIM</sup>: 100 (29.2-100)

### Best overall response – n (%)

- **CR**
  - Cohort A: 0
  - Cohort B: 0
  - ALL: 0
  - MYD88<sup>WT</sup> CXCR4<sup>WHIM</sup>: 0
  - MYD88<sup>L265P</sup> CXCR4<sup>WT</sup>: 0
  - MYD88<sup>L265P</sup> CXCR4<sup>WHIM</sup>: 0

- **VGPR**
  - Cohort A: 3 (16.7)
  - Cohort B: 3 (11.1)
  - ALL: 0
  - MYD88<sup>WT</sup> CXCR4<sup>WHIM</sup>: 3 (13.6)
  - MYD88<sup>L265P</sup> CXCR4<sup>WT</sup>: 0
  - MYD88<sup>L265P</sup> CXCR4<sup>WHIM</sup>: 0

- **PR**
  - Cohort A: 13 (72.2)
  - Cohort B: 8 (88.9)
  - ALL: 21 (77.8)
  - MYD88<sup>WT</sup> CXCR4<sup>WHIM</sup>: 1 (100)
  - MYD88<sup>L265P</sup> CXCR4<sup>WT</sup>: 17 (77.3)
  - MYD88<sup>L265P</sup> CXCR4<sup>WHIM</sup>: 2 (66.7)

- **MR**
  - Cohort A: 1 (5.6)
  - Cohort B: 1 (11.1)
  - ALL: 2 (7.4)
  - MYD88<sup>WT</sup> CXCR4<sup>WHIM</sup>: 0
  - MYD88<sup>L265P</sup> CXCR4<sup>WT</sup>: 1 (4.5)
  - MYD88<sup>L265P</sup> CXCR4<sup>WHIM</sup>: 1 (33.3)

- **SD**
  - Cohort A: 1 (5.6)
  - Cohort B: 0
  - ALL: 1 (3.7)
  - MYD88<sup>WT</sup> CXCR4<sup>WHIM</sup>: 0
  - MYD88<sup>L265P</sup> CXCR4<sup>WT</sup>: 1 (4.5)
  - MYD88<sup>L265P</sup> CXCR4<sup>WHIM</sup>: 0

- **PD**
  - Cohort A: 0
  - Cohort B: 0
  - ALL: 0
  - MYD88<sup>WT</sup> CXCR4<sup>WHIM</sup>: 0
  - MYD88<sup>L265P</sup> CXCR4<sup>WT</sup>: 0
  - MYD88<sup>L265P</sup> CXCR4<sup>WHIM</sup>: 0

### Median TTMR – mo (range)

- Cohort A: 1.87 (1.0-5.7)
- Cohort B: 2.07 (1.0-3.7)
- ALL: 2.00 (1.0-5.7)
- MYD88<sup>WT</sup> CXCR4<sup>WHIM</sup>: 5.55 (5.6-5.6)
- MYD88<sup>L265P</sup> CXCR4<sup>WT</sup>: 1.94 (1.0-5.6)
- MYD88<sup>L265P</sup> CXCR4<sup>WHIM</sup>: 2.89 (1.9-3.9)

### Median TTOR – mo (range)

- Cohort A: 0.95 (0.9-3.9)
- Cohort B: 0.99 (0.9-1.9)
- ALL: 0.95 (0.9-3.9)
- MYD88<sup>WT</sup> CXCR4<sup>WHIM</sup>: 0.95 (1.0-1.0)
- MYD88<sup>L265P</sup> CXCR4<sup>WT</sup>: 0.95 (0.9-1.9)
- MYD88<sup>L265P</sup> CXCR4<sup>WHIM</sup>: 2.07 (1.0-3.9)

**Abbreviations:** 95% CI, 95% confidential interval; CR, complete response; MR, minor response; MRR, major response rate; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease; TTMR, time to major responses; TTOR, time to overall responses; VGPR, very good partial response.

*aGene mutation data were missing in 1 patient in Cohort A.*
patients with MYD88L265P/CXCR4WT (1.94 mo) and those with MYD88L265P/CXCR4WHIM (2.89 mo).

Regarding PFS and OS, no events were observed during the study period, with the exception that 1 patient (11.1%) in Cohort B, whose best overall response was PR, had PD at 240 d after the start of the study drug administration. All patients in both cohorts experienced a decrease in serum IgM levels (Figure 3A). The best reductions in individual serum IgM levels were greater than 50% in 25 (92.6%) patients in total, with 16 (88.9%) and 9 (100%) patients in Cohorts A and B, respectively. Among 14 patients in total with prior lymphadenopathy, SPD data were available for 13 patients (8 and 5 patients in Cohorts A and B, respectively). All the patients experienced marked shrinkage in lesion size, with > 50% best reduction in SPD observed in 87.5% and 80% of patients in Cohorts A and B, respectively (Figures 3B and S1). Low basal levels of hemoglobin, particularly in Cohort A, recovered during the treatment (Figure 3C).

Baseline clinical symptoms associated with WM were observed in 21 patients in total, with 16 and 5 patients in Cohorts A and B, respectively (Table S2). Among them, 15 patients (71.4%) in total, including 11 (68.8%) in Cohort A and 4 (80.0%) in Cohort B, experienced resolution of all symptoms at least once after administration of the study drug.

### 3.3 Safety

All patients experienced AEs. The common AEs were rash (44.4%), neutropenia (25.9%), leukopenia (22.2%), and stomatitis (14.8%) (Table 3). Grade 3 and 4 AEs were observed in 8 patients (29.6%), including 3 with neutropenia (11.1%), 3 with lymphopenia (11.1%), and 2 with leukopenia (7.4%). No grade 5 AEs were identified. Serious AEs, including transient ischemic attack on day 49, classified as grade 2, and rhegmatogenous retinal detachment on day 184, classified as grade 3, were observed in 2 patients in Cohort A (7.4%). These serious AEs appeared to be unrelated to tirabrutinib treatment, and the patients recovered after treatment interruption. Three patients experienced tirabrutinib-related grade 1 bleeding events, including epistaxis (2 patients) and mouth hemorrhage (1 patient). These patients continued the study drug administration without interruption but were administered a reduced dose of tirabrutinib.

![Figure 3](image-url)

**Figure 3** Best reductions in serum IgM and SPD and chronological changes in median hemoglobin levels. **A**, Left panel: A waterfall plot shows the best reductions in serum IgM level in each patient. Dotted lines represent 25%, 50%, and 90%, which are the thresholds of each response. Right panel: Chronological changes in median serum IgM levels are shown. The error bars represent the interquartile ranges. **B**, The best reductions in SPD are shown as a waterfall plot. The SPD data for 1 patient in Cohort B were missing. **C**, Chronological changes in median hemoglobin levels are shown. The error bars represent the interquartile ranges.
A dose of tirabrutinib. One patient was considered to have worsening chronic atrial fibrillation; however, electrocardiography and echocardiography revealed no apparent changes. The chronic atrial fibrillation was considered to be due to exercise reported by the patient and not due to drugs.

One patient discontinued tirabrutinib administration due to the worsening of an atypical mycobacterial infection at day 57 (grade 3), which resolved after discontinuation. AEs leading to study drug interruption were observed in 7 patients (38.9%) in Cohort A and 5 patients (55.6%) in Cohort B and included skin-related AEs in 5 patients and neutropenia in 2 patients. No noticeable symptoms associated with the primary disease, with the exception of a transient increase in IgM levels in 3 (25%) of the 12 patients, were observed during the study drug interruption. Upon resuming administration of the study drug, reduced doses were administered to 6 patients (33.3%) in Cohort A and temporarily to 1 patient (11.1%) in Cohort B.

No patients exhibited IgM flares during the study drug administration. The transient increases in IgM levels observed during the study drug interruption were resolved after resuming administration. Basal serum IgA and IgG levels were mostly sustained or slightly decreased during the administration (Figure S2), and no patients required new administration of globulin preparation. Basal IgG levels in 3 patients in Cohort A were beyond the upper normal limit but decreased to within the normal limit or lower upon tirabrutinib administration. Focusing on lymphocytosis after tirabrutinib administration, 1 patient had grade 2

| Adverse events – n (%) | Cohort A Treatment-naive N = 18 | Cohort B Relapsed/refractory N = 9 | Total N = 27 |
|------------------------|----------------------------------|-----------------------------------|-------------|
| All                    | 18 (100)                         | 9 (100)                           | 27 (100)    |
| Rash                   | 11 (61.1)                        | 1 (11.1)                          | 12 (44.4)   |
| Neutropenia            | 2 (11.1)                         | 5 (55.6)                          | 7 (25.9)    |
| Leukopenia             | 2 (11.1)                         | 4 (44.4)                          | 6 (22.2)    |
| Stomatitis             | 3 (16.7)                         | 1 (11.1)                          | 4 (14.8)    |
| Thrombocytopenia       | 3 (16.7)                         | 0                                 | 3 (11.1)    |
| Rash maculopapular     | 3 (16.7)                         | 0                                 | 3 (11.1)    |
| Nausea                 | 2 (11.1)                         | 1 (11.1)                          | 3 (11.1)    |
| Nasopharyngitis        | 1 (5.6)                          | 2 (22.2)                          | 3 (11.1)    |
| Lymphopenia            | 1 (5.6)                          | 2 (22.2)                          | 3 (11.1)    |
| Diarrhea               | 2 (11.1)                         | 0                                 | 2 (7.4)     |
| Urinary tract infection| 2 (11.1)                         | 0                                 | 2 (7.4)     |
| Pruritus               | 2 (11.1)                         | 0                                 | 2 (7.4)     |
| Cataract               | 1 (5.6)                          | 1 (11.1)                          | 2 (7.4)     |
| Constipation           | 1 (5.6)                          | 1 (11.1)                          | 2 (7.4)     |
| Pyrexia                | 1 (5.6)                          | 1 (11.1)                          | 2 (7.4)     |
| Weight decreased       | 1 (5.6)                          | 1 (11.1)                          | 2 (7.4)     |
| Insomnia               | 1 (5.6)                          | 1 (11.1)                          | 2 (7.4)     |
| Epistaxis              | 1 (5.6)                          | 1 (11.1)                          | 2 (7.4)     |
| Bronchitis             | 0                                | 2 (22.2)                          | 2 (7.4)     |
| Rhegmatogenous retinal| 1 (5.6)                          | 0                                 | 1 (3.7)     |
| Atypical mycobacterial | 1 (5.6)                          | 0                                 | 1 (3.7)     |
| Erythema multiforme    | 1 (5.6)                          | 0                                 | 1 (3.7)     |
| Rash erythematous      | 1 (5.6)                          | 0                                 | 1 (3.7)     |
| Type 2 diabetes mellitus| 1 (5.6)                          | 0                                 | 1 (3.7)     |

Note: Adverse events observed in more than 2 patients and those with grade ≥ 3 were listed.
treatment-related lymphocytosis (lymphocyte count: 5.5 \times 10^9/L) at day 10, and the AE was resolved without discontinuation of tirabrutinib administration.

**4 | DISCUSSION**

In this study, we present the results of a prospective single-arm phase II study of tirabrutinib monotherapy in patients with treatment-naïve and relapsed or refractory WM. We observed high ORR (96.3%) and MRR (88.9%) in all patients. The TTOR and TTMR were 0.95 and 2 mo, respectively. Although the long-term survival could not be satisfactorily evaluated in the follow-up period, the rapid improvement in hemoglobin levels and the gradual decrease in serum IgM levels were noted. Indeed, the hemoglobin levels increased from 10.45 g/dL at baseline to 11.95 g/dL, and the median serum IgM levels decreased from 3788 mg/dL to 2350 mg/dL after 4 wk of tirabrutinib administration in Cohort A. Approximately half of the patients (51.9%) had lymphadenopathy, and all experienced immediate reduction in lesion size or resolution. These results are comparable with those obtained for ibrutinib monotherapy in treatment-naïve WM and the rituximab-ibrutinib group in the INNOVATE study.

Our study has the limitation of tirabrutinib responses by MYD88 and CXCR4 mutational status because these mutations were assessed using different methods: MYD88 using AS-PCR and CXCR4 using NGS. Ibrutinib monotherapy responses have been reported to be affected by MYD88 and CXCR4 mutational status, whereas the responses in patients treated with ibrutinib and rituximab appeared to be independent of mutational status. In the present study, 25 of 26 patients (96.2%) with genetic mutational data had MYD88L265P mutation. Although only 4 patients had CXCR4WHIM mutation, including 3 with MYD88L265P mutation, the median times to response in these patients were comparable with those of the patients with MYD88L265P/CXCR4VT.

The efficacies and safety of various BTK inhibitors, including ibrutinib for patients with WM, are summarized in Table S3. Ibrutinib is often accompanied by AEs such as atrial fibrillation, bleeding events, and hypertension, leading many patients to discontinue treatment. For instance, with ibrutinib monotherapy, grade 2 or higher AEs, including atrial fibrillation (5%-10%), bleeding events (6%-13%), and hypertension (5%-13%), have been reported, and 32% of patients discontinued ibrutinib treatment for any reason in relapsed or refractory WM. Matot et al. conducted a multicenter retrospective analysis of 616 patients with CLL treated with ibrutinib either commercially or in clinical trials. In the report, 41% of the patients discontinued ibrutinib, with toxicity reported as the most common reason for discontinuation. The median time to ibrutinib discontinuation was 7 mo. In contrast, the present study, tirabrutinib-related grade 1 bleeding events occurred in 3 patients, and there were no grade 2 or higher drug-related bleeding events. Three patients discontinued tirabrutinib during follow-up: 1 patient discontinued because of PD after exhibiting PR, whereas the other discontinuations were not because of tirabrutinib-related AEs. Thus, we conclude that tirabrutinib monotherapy was well tolerated, with no unexpected toxicities observed.

It is noteworthy that there were no incidents of drug-related atrial fibrillation or hypertension in response to tirabrutinib. In contrast, a systematic review and meta-analysis of WM and mantle cell lymphoma in addition to CLL showed that ibrutinib significantly increased the risk of both atrial fibrillation and hypertension. Ibrutinib potently inhibits essential human EGFR-related tyrosine kinases such as HER2 and HER4. Conversely, tirabrutinib may not affect these tyrosine kinases. Therefore, the difference in selectivity between ibrutinib and tirabrutinib may result in different influences on cardiovascular AEs.

In the present study, 1 case had transient grade 2 lymphocytosis after tirabrutinib administration, which was resolved without any specific treatment or discontinuation of tirabrutinib. Treatment-related lymphocytosis has not been reported as common or serious AEs in most of BTK inhibitor clinical trial for WM patients. Thus, lymphocytosis accompanied by BTK inhibitor initiation in WM might not be a problematic issue, although further investigation will be required.

Second-generation BTK inhibitors, including tirabrutinib and acalabrutinib, have been designed to have fewer off-target effects with the goal of improving efficacy and reducing toxicity. Two reports of phase II studies of acalabrutinib monotherapy in ibrutinib-intolerant patients for relapsed or refractory CLL are available to date, and these studies reported high response rates and satisfied safety criteria. Most recently, a phase II study of acalabrutinib monotherapy for mainly patients with relapsed or refractory WM demonstrated high efficacy and feasibility, with a low discontinuation rate. Considering these reports, second-generation BTK inhibitors may contribute to reducing toxicities recognized by ibrutinib, with better dose adherence expected for patients with WM.

In summary, the present study demonstrated that tirabrutinib monotherapy is highly effective with rapid responses and is well tolerated in both treatment-naïve patients and those with relapsed/refractory symptomatic WM. The MRR as the primary endpoint was met. However, some efficacy endpoints, such as PFS and OS, could not be evaluated because of the limited observation period. Therefore, future studies with a longer follow-up period are warranted.

**ACKNOWLEDGMENTS**

We thank the patients participating in this trial and their supportive families. We thank Dr. Kazuo Tamura (Fukuoka University, Japan) and Dr. Hirokazu Nagai (Nagoya Medical Center, Japan) for reviewing clinical data as members of the efficacy and safety monitoring committee, and the investigators and staffs at all study sites for contributions to this trial. A medical writing support was provided, in part, by Dr. Masatoshi Esaki (Ono Pharmaceutical Co., LTD, Japan), and this study was funded by Ono Pharmaceutical Co., Ltd.
DISCLOSURE
N. Sekiguchi has received research funding from Ono Pharmaceutical. W. Munakata has received research funding from Ono Pharmaceutical. H. Handa has received research funding from Ono Pharmaceutical. H. Shibayama has received honoraria from Takeda, Novartis, Celgene, Janssen, Chugai, and Kyowa Kirin; research funding from Janssen, Ono Pharmaceutical, Celgene, Novartis, Sanofi, AstraZeneca, AbbVie, and Chugai; and scholarship endowment from Astellas, Teijin, Shionogi, Eisai, Sanofi, Taiho, and Nippon Shin'yaku. Y. Terui has received honoraria from Chugai, Celgene, Bristol-Myers Squibb, Novartis, Janssen, and Ono Pharmaceutical; and research funding from Bristol-Myers Squibb. N. Fukuhara has received honoraria from Chugai pharma and Kyowa Kirin; and research funding from AbbVie, Bayer, Chugai, Eisai, Gilead Sciences, Incyte, Ono Pharmaceutical, and Solasia. S. Iida has received honoraria from Ono Pharmaceutical, Takeda, Janssen, Celgene, Bristol-Myers Squibb, Daiichi Sankyo, and Sanofi; and research funding from Ono Pharmaceutical, Takeda, Bristol-Myers Squibb, MSD, Janssen, AbbVie, Kyowa Kirin, Chugai, and Sanofi. K. Izutsu has received honoraria from Kyowa Kirin and Eisai; and research funding from Celgene, Chugai, Novartis, Ono, Pharmaceutical, Bayer, Zenyaku Kogyo, Kyowa Kirin, AstraZeneca, Eisai, Incyte, AbbVie, Symboio, Janssen, and Yakult. The other authors have no relationships to disclose. This work was supported by Ono Pharmaceutical. The study sponsor was involved in study design, writing of the report, and in the decision to submit the article for publication. Study drug was provided by Ono Pharmaceutical. All authors had full access to all of the data in the study and had final responsibility for the decision to submit for publication.

ETHICAL CONSIDERATIONS
The institutional review board of each site approved this trial. This trial was conducted in accordance with the Declaration of Helsinki, and all patients provided written informed consent.

DATA AVAILABILITY STATEMENT
Qualified researchers may request access to individual patient data through Clinical Study Data Request.com (https://www.clinicalstud ydatarequest.com/). The policy for data sharing of the sponsor is available at https://www.ono.co.jp/eng/rd/policy.html.

ORCID
Naohiro Sekiguchi https://orcid.org/0000-0001-9860-8257
Shinsuke Iida https://orcid.org/0000-0002-4951-960X

REFERENCES
1. Swerdlow S, Cook J, Sohani A, et al. Lymphoplasmacytic lymphoma. In: Swerdlow S, Campo E, Harris N, eds. WHO Classification of Tumour of Hematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2017:232–235.
2. Owen RG, Treon SP, Al-Katib A, et al. Clinopathological definition of Waldenström’s macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia. Semin Oncol. 2003;30:110–115.
3. Buske C, Sadullah S, Kastritis E, et al. Treatment and outcome patterns in European patients with Waldenström’s macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018;5:e299–e309.
4. Olszewski AJ, Treon SP, Castillo JJ. Application and Outcomes of Bendamustine- or Bortezomib-Based Therapy for Waldenström’s Macroglobulinemia [abstract]. Blood. 2017;130(Supplement 1):348.
5. Olszewski AJ, Treon SP, Castillo JJ. Evolution of management and outcomes in Waldenström Macroglobulinemia: a population-based analysis. Oncologist. 2016;21:1377–1386.
6. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05–180. J Clin Oncol. 2009;27:3830–3835.
7. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25:3344–3349.
8. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–1210.
9. Dimopoulos MA, Kastritis E. How I treat Waldenström’s Macroglobulinemia. Blood. 2019;134:2022–2035.
10. Qiu Y, Kung H-J. Signaling network of the Btk family kinases. Oncogene. 2000;19:5651–5661.
11. Kurozaki T, Hikida M. Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev. 2009;228:132–148.
12. Genevri H, Hinshelwood S, Gaspar HB, et al. Expression of Bruton’s tyrosine kinase protein within the B cell lineage. Eur J Immunol. 1994;24:3100–3105.
13. Ponader S, Burger JA. Bruton’s tyrosine kinase: From X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol. 2014;32:1830–1839.
14. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88–92.
15. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367:826–833.
16. Treon SP, Hunter ZR. A new era for Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05–180. J Clin Oncol. 2007;25:3344–3349.
17. Yang G, Zhou Y, Liu X, et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. 2013:122:1222–1232.
18. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström’s macroglobulinemia. N Engl J Med. 2015;372:1430–1440.
19. Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström macroglobulinaemia. J Clin Oncol. 2018;36:2755–2761.
20. Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of Ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med. 2018;378:2399–2410.
21. Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133:1298–1307.
22. Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the united states: A real-world analysis. Haematologica. 2018;103:874–879.
23. Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis. PLoS One. 2019;14:e0211228.
24. Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129:2621–2622.

25. Yun S, Vincellette ND, Achariya U, Abraham I. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin. Lymphoma Myeloma Leuk. 2017;17:31–37.e13.

26. Liclican A, Serafini L, Xing W, et al. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton’s tyrosine kinase reveals differences in on- and off-target inhibition. Biochim BiophysActa Gen Subj. 2020;1864:129531.

27. Kozaki R, Vogler M, Walter H, et al. Responses to the selective Bruton’s Tyrosine Kinase (BTK) inhibitor tirabrutinib (ONO/GS-4059) in diffuse large B-cell lymphoma cell lines. Cancers (Basel). 2018;10:127.

28. Owen C, Berinstein NL, Christofides A, Sehn LH. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol. 2019;26:233–240.

29. Walter HS, Rule SA, Dyer MJS, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127:411–419.

30. Munakata W, Ando K, Hatake K, et al. Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. Cancer Sci. 2019;110:1686–1694.

31. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenström’s macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenström’s Macroglobulinemia. Semin Oncol. 2003;30:116–120.

32. Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014;124:1404–1411.

33. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenström macroglobulinemia. Blood. 2009;113:4163–4170.

34. Jiménez C, del Chillo MC, Balanzategui A, et al. Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction. Appl Immunohistochem Mol Morphol. 2014;22:768–773.

35. Rothenberg JM, Hinz W, Rearick TM, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature. 2011;475:348–352.

36. Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenström macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123:1637–1646.

37. Treon SP, Cao Y, Xu L, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenström macroglobulinemia. Blood. 2014;123:2791–2796.

38. Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenström macroglobulinemia: update from the VIIth International Workshop. Br J Haematol. 2013;160:171–176.

39. Abeykoon JP, Zanwar S, Ansell SM, et al. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinemia: practice patterns, toxicities and outcomes. Br J Haematol. 2020;188:394–403.

40. Gertz MA, Rue M, Blood E, et al. Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma. 2004;45:2047–2055.

41. Leblond V, Johnson S, Chevret S, et al. Results of a randomized Trial of Chlorambucil versus Fludarabine for patients with untreated Waldenström Macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31:301–307.

42. Lee K-F, Simon H, Chen H, et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378:394–398.

43. Gassmann M, Casagrande F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 1995;378:390–394.

44. Gassmann M, Casagrande F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 1995;378:390–394.

45. Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020;7:e112–e121.

46. Leblond V, Johnson S, Chevret S, et al. Results of a randomized Trial of Chlorambucil versus Fludarabine for patients with untreated Waldenström Macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013;31:301–307.

47. Rogers KA, Thompson PA, Allan JN, et al. Phase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). [abstract]. J. Clin. Oncol. 2019;37(15_suppl):7530.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Sekiguchi N, Rai S, Munakata W, et al. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström’s macroglobulinemia. Cancer Sci. 2020;111:3327–3337. https://doi.org/10.1111/cas.14561